Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

NASDAQ:SXTP - Nasdaq - US83006G4010 - Common Stock - Currency: USD

2.37  +0.07 (+3.04%)

Fundamental Rating

2

SXTP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. SXTP has a bad profitability rating. Also its financial health evaluation is rather negative. SXTP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SXTP has reported negative net income.
In the past year SXTP has reported a negative cash flow from operations.
In the past 5 years SXTP always reported negative net income.
In the past 5 years SXTP always reported negative operating cash flow.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

SXTP has a worse Return On Assets (-179.62%) than 88.21% of its industry peers.
SXTP's Return On Equity of -261.25% is on the low side compared to the rest of the industry. SXTP is outperformed by 73.33% of its industry peers.
Industry RankSector Rank
ROA -179.62%
ROE -261.25%
ROIC N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

SXTP's Gross Margin of 50.40% is fine compared to the rest of the industry. SXTP outperforms 63.08% of its industry peers.
SXTP's Gross Margin has declined in the last couple of years.
SXTP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

3

2. Health

2.1 Basic Checks

SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
SXTP has more shares outstanding than it did 1 year ago.
SXTP has a worse debt/assets ratio than last year.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

SXTP has an Altman-Z score of -13.62. This is a bad value and indicates that SXTP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SXTP (-13.62) is worse than 75.90% of its industry peers.
SXTP has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.04, SXTP is in line with its industry, outperforming 54.36% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -13.62
ROIC/WACCN/A
WACC9.71%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 3.13 indicates that SXTP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.13, SXTP is in line with its industry, outperforming 55.90% of the companies in the same industry.
A Quick Ratio of 2.71 indicates that SXTP has no problem at all paying its short term obligations.
SXTP has a Quick ratio of 2.71. This is comparable to the rest of the industry: SXTP outperforms 51.79% of its industry peers.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 2.71
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SXTP have decreased strongly by -194.32% in the last year.
The Revenue has grown by 109.23% in the past year. This is a very strong growth!
Measured over the past years, SXTP shows a very negative growth in Revenue. The Revenue has been decreasing by -52.49% on average per year.
EPS 1Y (TTM)-194.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-186.67%
Revenue 1Y (TTM)109.23%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%11.58%

3.2 Future

The Earnings Per Share is expected to grow by 25.73% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 82.46% on average over the next years. This is a very strong growth
EPS Next Y90.03%
EPS Next 2Y38.34%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year109.78%
Revenue Next 2Y94.74%
Revenue Next 3Y82.46%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SXTP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

SXTP's earnings are expected to grow with 25.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.34%
EPS Next 3Y25.73%

More info and screens

0

5. Dividend

5.1 Amount

SXTP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

60 DEGREES PHARMA INC

NASDAQ:SXTP (6/30/2025, 4:35:59 PM)

2.37

+0.07 (+3.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)N/A N/A
Inst Owners2.05%
Inst Owner Change-80.39%
Ins Owners2.37%
Ins Owner Change2.76%
Market Cap3.48M
Analysts80
Price Target5.92 (149.79%)
Short Float %1.27%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-131.74%
Min EPS beat(2)-247.17%
Max EPS beat(2)-16.31%
EPS beat(4)0
Avg EPS beat(4)-85.29%
Min EPS beat(4)-247.17%
Max EPS beat(4)-16.31%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.41%
Min Revenue beat(2)-29.6%
Max Revenue beat(2)-3.22%
Revenue beat(4)0
Avg Revenue beat(4)-30.05%
Min Revenue beat(4)-45.31%
Max Revenue beat(4)-3.22%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-65.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)55.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-125%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.4
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-41.56
EYN/A
EPS(NY)-3.29
Fwd EYN/A
FCF(TTM)-4.27
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS0.54
BVpS2.8
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -179.62%
ROE -261.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.4%
FCFM N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
F-Score3
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 302.74%
Cap/Sales 22.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 2.71
Altman-Z -13.62
F-Score3
WACC9.71%
ROIC/WACCN/A
Cap/Depr(3y)258.14%
Cap/Depr(5y)228.76%
Cap/Sales(3y)28.01%
Cap/Sales(5y)17.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-194.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-186.67%
EPS Next Y90.03%
EPS Next 2Y38.34%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue 1Y (TTM)109.23%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%11.58%
Revenue Next Year109.78%
Revenue Next 2Y94.74%
Revenue Next 3Y82.46%
Revenue Next 5YN/A
EBIT growth 1Y-85.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.33%
OCF growth 3YN/A
OCF growth 5YN/A